| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20030137 | HPV | ENSG00000103546.19 | protein_coding | SLC6A2 | No | No | 6530 | P23975 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SLC6A2 |
|---|---|
| DrugBank ID | DB00988 |
| Drug Name | Dopamine |
| Target ID | BE0000486 |
| UniProt ID | P23975 |
| Regulation Type | inhibitor |
| PubMed IDs | 11071707 |
| Citations | Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001 Jan;39(1):32-41. |
| Groups | Approved |
| Direct Classification | Catecholamines and derivatives |
| SMILES | NCCC1=CC(O)=C(O)C=C1 |
| Pathways | Remifentanil Action Pathway; Hydrocodone Action Pathway; Sufentanil Action Pathway; Morphine Action Pathway; Fluoxetine Action Pathway; 3-Methylthiofentanyl Action Pathway; Benzocaine Action Pathway; Oxybuprocaine Action Pathway; Codeine Action Pathway; Alkaptonuria; Tyrosine Hydroxylase Deficiency; Ketobemidone Action Pathway; Propoxyphene Action Pathway; Dihydromorphine Action Pathway; Nicotine Action Pathway; Proparacaine Action Pathway; Methadyl Acetate Action Pathway; Hawkinsinuria; Oxymorphone Action Pathway; Fentanyl Action Pathway; Dimethylthiambutene Action Pathway; Dopamine beta-Hydroxylase Deficiency; Lidocaine (Local Anaesthetic) Action Pathway; Monoamine Oxidase-A Deficiency (MAO-A); Aromatic L-Aminoacid Decarboxylase Deficiency; Hydromorphone Action Pathway; Tyrosinemia, Transient, of the Newborn; Anileridine Action Pathway; Bupivacaine Action Pathway; Dopamine Activation of Neurological Reward System |
| PharmGKB | PA449396 |
| ChEMBL | CHEMBL59 |
